uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment⦠read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
$54.44
Price-6.74%
-$3.93
$2.987b
Mid
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$14.337m
-
1y CAGR-
3y CAGR-
5y CAGR-$198.995m
-
1y CAGR-
3y CAGR-
5y CAGR-$3.92
-
1y CAGR-
3y CAGR-
5y CAGR-$4.003m
$584.890m
Assets$588.893m
Liabilities$66.697m
Debt11.4%
-0.5x
Debt to EBITDA-$174.264m
-
1y CAGR-
3y CAGR-
5y CAGR